Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FB-101
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FB-101 Oral SAD/MAD Safety, Tolerability and PK/PD In Healthy Males
Details : FB-101 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 17, 2025
Lead Product(s) : FB-101
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
Details : FB418 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : FB849
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FB849 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 09, 2023
Lead Product(s) : FB849
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
Details : FB-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2019
Reset All
